Kinetic determination of codeine in pharmaceutical preparations

A kinetic method for the determination of codeine, based on its inhibitor action on the catalytic decomposition of hydrogen peroxide by cobalt(II), is presented. It has been found that the effect of codeine is most pronounced in the presence of 5% v/v ethylene glycol. The reaction is followed photometrically. Codeine can be determined in concentrations ranging from 0.80×10^–5 M to 2.4×10^–5 M. The method has been applied to the determination of codeine in pharmaceutical preparations.     

Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence,Ideas and Challenges

When the first- and second-line therapeutics used to treat neuropathic pain (NP) fail to induce efficient analgesia—which is estimated to relate to more than half of the patients—opioid drugs are prescribed. Still, the pathological changes following the nerve tissue injury, i.a. pronociceptive neuropeptide systems activation, oppose the analgesic effects of opiates, enforcing the use of relatively high therapeutic doses in order to obtain satisfying pain relief. In parallel, the repeated use of opioid agonists is associated with burdensome adverse effects due to compensatory mechanisms that arise thereafter. Rational design of hybrid drugs, in which opioid ligands are combined with other pharmacophores that block the antiopioid action of pronociceptive systems, delivers the opportunity to ameliorate the NP-oriented opioid treatment via addressing neuropathological mechanisms shared both by NP and repeated exposition to opioids. Therewith, the new dually acting drugs, tailored for the specificity of NP, can gain in efficacy under nerve injury conditions and have an improved safety profile as compared to selective opioid agonists. The current review presents the latest ideas on opioid-comprising hybrid drugs designed to treat painful neuropathy, with focus on their biological action, as well as limitations and challenges related to this therapeutic approach.     

In vitro metabolism of specific CYP2D and CYP3A opioid substrates using rat liver S9 fractions and mass spectrometry reveal a severe metabolic impairment with increasing age

Codeine and oxycodone are opioids used to alleviate pain. The outcome of the treatment is ultimately related to their metabolism by Cytochromes P450 (CYPs). Depending on the drugs used, alterations in the metabolism of drugs by CYPs can lead to severe consequences including alterations in their efficacy, safety and toxicity. The objectives of this study were to develop a novel HPLC–MS/MS method capable of quantifying codeine and oxycodone along with specific metabolites using an isotopic dilution strategy and study the rate of formation of morphine (CYP2D), norcodeine (CYP3A), oxymorphone (CYP2D) and noroxycodone (CYP3A). The chromatographic separation was achieved using a Biobasic C₁₈ 100 × 1 mm column combined with an isocratic mobile phase composed of methanol and 10 mm ammonium acetate (40:60) at a flow rate of 75 μL/min. The mass spectrometer was operating in scan mode MS/MS and the analytical range was set at 10–10 000 nm . The precision (RSD) and accuracy (RE) observed were 4.4–11.5 and −9.1–6.1% respectively. Liver S9 fractions from 3‐, 6‐, 12‐ and 18‐month‐old male Sprague–Dawley rats were prepared and Michaelis–Menten parameters were determined. The derived maximum enzyme velocity suggested a rapid saturation of the CYP2D and CYP3A active sites in the liver S9 fractions of 18‐month‐old rats. Moreover, metabolic stabilities of codeine and oxycodone in rat liver S9 fractions were significantly greater for the 18‐month‐old rats. This study suggests that there is an impairment of CYP2D and CYP3A metabolism in aging rats.     

Determination of pharmaceuticals of various therapeutic classes by solid-phase extraction and liquid chromatography-tandem mass spectrometry analysis in hospital effluent wastewaters

A multi-residue analytical method has been developed and validated for determining a selection of 16 pharmaceuticals: the anti-epileptic carbamazepine, seven analgesic/anti-inflammatory drugs (mefenamic acid, indomethacine, ibuprofen, naproxen, diclofenac, ketorolac and acetaminophen), the analgesic opiate codeine, two antidepressants (fluoxetine and paroxetine), beta-blockers (atenolol and propranolol), antibiotic (trimethoprim, metronidazole, and erythromycin) and the anti-ulcer ranitidine in hospital effluent wastewaters. The method allows simultaneous extraction of the pharmaceuticals compounds by solid-phase extraction (SPE) using the Waters Oasis HLB at pH 7. The analytes were then identified and quantitatively determined by liquid chromatography-tandem mass spectrometry (LC-MS-MS) using multiple reaction monitoring (MRM). Recoveries of the pharmaceuticals were higher than 75%, with the exception of ranitidine (45%) and the overall variability of the method was below 9%. The instrumental detection limit (IDL) varied between 2 and 31 pg injected, the method detection limit (LOD) was between 7 and 47 ng/L in spiked hospital effluent. The precision of the method, calculated as relative standard deviation (RSD), ranged from 0.3 to 4.9%. A detail study off matrix effect is included in this work, regarding to signal suppression in these effluent wastewaters from a hospital complex samples. The developed analytical method was applied for preliminary data results in effluent wastewaters from a hospital.     

Recent Chemical and Pharmacological Developments on 14-Oxygenated-N-methylmorphinan-6-ones

Adequate pain management, particularly chronic pain, remains a major challenge associated with modern-day medicine. Current pharmacotherapy offers unsatisfactory long-term solutions due to serious side effects related to the chronic administration of analgesic drugs. Morphine and structurally related derivatives (e.g., oxycodone, oxymorphone, buprenorphine) are highly effective opioid analgesics, mediating their effects via the activation of opioid receptors, with the mu-opioid receptor subtype as the primary molecular target. However, they also cause addiction and overdose deaths, which has led to a global opioid crisis in the last decades. Therefore, research efforts are needed to overcome the limitations of present pain therapies with the aim to improve treatment efficacy and to reduce complications. This review presents recent chemical and pharmacological advances on 14-oxygenated-N-methylmorphinan-6-ones, in the search of safer pain therapeutics. We focus on drug design strategies and structure–activity relationships on specific modifications in positions 5, 6, 14 and 17 on the morphinan skeleton, with the goal of aiding the discovery of opioid analgesics with more favorable pharmacological properties, potent analgesia and fewer undesirable effects. Targeted molecular modifications on the morphinan scaffold can afford novel opioids as bi- or multifunctional ligands targeting multiple opioid receptors, as attractive alternatives to mu-opioid receptor selective analgesics.     

磺基水杨酸修饰电极联吡啶钌电化学发光体系测定可待因的研究

基于磷酸可待因对联吡啶钌在该电极上的电化学及其发光行为的增敏作用,建立了一种直接测定磷酸可待因的电化学发光新方法。在最佳实验条件下,磷酸可待因在1.0×10-4～4.0×10-6mol/L和4.0×10-6～2.0×10-7mol/L与相对发光强度呈线性关系,检出限为1.0×10-7mol/L(S/N=3)。连续测定4.0×10-7mol/l磷酸可待因5次,发光强度的RSD为2.7%。方法用于模拟尿样中磷酸可待因的测定,结果满意。     

Structure investigation of codeine drug using mass spectrometry, thermal analyses and semi-emperical molecular orbital (MO) calculations

Codeine is an analgesic with uses similar to morphine, but it has a mild sedative effect. It is preferable used as phosphate form and it is often administrated by mouth with aspirin or paracetamol. Therefore, it is important to investigate its structure to know the active groups and weak bonds responsible for its medical activity. Consequently in the present work, codeine was investigated by mass spectrometry and thermal analyses (TG, DTG and DTA) and confirming by semi-empirical MO-calculation (PM3 method) in the neutral and positively charged forms of the drug. Some results of studying the d-block element complexes of codeine were used to declare the relationship between drug structure and its chemical reactivity in vitro system. The mass spectra and thermal analyses fragmentation pathways were proposed and compared to each other to select the most suitable scheme representing the correct fragmentation of this drug. From EI mass spectra, the main primary cleavage site of the charged drug molecule is that due to beta-cleavage to nitrogen atom in its skeleton. It occurs in two parallel mechanisms with the same possibility, i.e. no difference in appearance activation energy between them. In the neutral drug form the primary site cleavage is that occurs in the ether ring. Thermal analyses of the neutral form of the drug revealed the high response of the drug to the temperature variation with very fast rate. It decomposed in several sequential steps in the temperature range 200-600 degrees C. The initial thermal fragments are very similar to that obtained by mass spectrometric fragmentation. Therefore, comparison between mass and thermal helps in selection of the proper pathway representing the fragmentation of this drug. This comparison successfully confirmed by MOC. These calculations give the bond order, charge distribution, heat of formation and possible hybridization of some atoms in different position of the drug skeleton. This helps the successful choice of the weakest bond at which both mass and thermal fragmentation occurs. Therefore, the best fragmentation pathway of this drug is correctly selected. The effect of such fragmentation on the drug behavior in the human body can be expected as a result of comparing these data with that obtained on studying codeine metal complexes using mass and thermal fragmentation techniques.     

Simultaneous determination of codeine and pyridoxine in pharmaceutical preparations by first-derivative spectrofluorimetry

A method for the simultaneous determination of codeine and pyridoxine was developed, based on the measurement of their native fluorescence signals, by using first-derivative spectrofluorimetry to resolve the mixture. Codeine was measured at lambda(em) = 309 nm, and pyridoxine was measured at lambda(em) = 450 nm. Instrumental parameters were optimized, and the emission spectra were recorded between 275 and 475 nm, at lambda(ex) = 255 nm and excitation and emission slit widths of 2.5 and 10 nm, respectively. Systematic studies on the influence of species usually present along with the analytes (such as caffeine, ascorbic acid, paracetamol, and thiamine) were also performed. The calibration graphs were linear over the ranges of 0.5-7.0 and 0.1-1.0 microg/mL for codeine and pyridoxine, respectively, and the relative standard deviations (n = 10) were about 3%. The method was successfully applied to the determination of codeine and pyridoxine in solutions of synthetic mixtures and in synthetic and semisynthetic pharmaceutical formulations.     

The use of IR, magnetism, reflectance, and mass spectra together with thermal analyses in structure investigation of codeine phosphate complexes of d-block elements

Codeine is an analgesic with uses similar to morphines, but it is of much less effect, i.e., it had a mild sedative effect; codeine is usually used as the phosphate form (Cod.P) and is often administrated by mouth with aspirin of paracetamol. Due to its serious use, if it is in large dose, attention is paid in this research to the synthesis and stereochemistry of new iron, cobalt, nickel, copper, and zinc complexes of this drug in both solution and the solid states. The spectra of these complexes in solution and the study of their stoichiometry refer to the formation of 1:1 ratio of metal (M) to ligand (L). The steriochemical structures of the solid complexes were studied on the basis of their analytical, spectroscopic, magnetic, and thermal data. Infrared spectra proved the presence of MO bonds. Magnetic susceptibility and solid reflectance spectral measurements were used to infer the structures. The prepared complexes were found to have the general formulae [ML(OH)(x)(H2O)(y)](H2O)(z)H3PO4, M: Co(II), Ni(II), and Cu(II), x = 1, y = 0, z = 0; M: Fe(II), x = 1, y = 2, z = 1; Fe(III), x = 2, y = 1, z = 0; Co(III), x = 0, y = 2, z = 1; Zn(II), x = 1, y = 0, z = 3; and L: (Cod.P) of the general formula C18H24NO7P (anhydrate). Octahedral, tetrahedral, and square planer structures were proposed for these complexes depending upon the magnetic and reflectance data and were confirmed by detailed mass and thermal analyses comparative studies.     

Mechanism of action of anti-opioid peptides at pain syndrome

An important goal of modern medicinal chemistry is to study the mechanisms of pain and analgesia in order to design effective analgesic drugs. Opioid analgesics are the gold standard for the treatment of severe pain; however, the use of opiates is associated with the development of side effects which are, in particular, related to the activation of the anti-opioid system. Mammalians synthesize a number of endogenous peptides, such as orphanin FGGFTGARKSARKLANQ, neuropeptide FF (FLFQPQRF-NH₂), tripeptide melanostatin (MIF) PLG-NH₂, as well as related compounds. These anti-opioid peptides are to one extent or another involved in homeostatic control of transmission of pain impulses. The present review includes the data published to date in domestic and foreign literature on the involvement of these peptides in such undesirable phenomena as inhibition of opioid analgesia, development of opioid tolerance and dependence, and hyperalgesia. Cell-cell and molecular ligand-receptor and receptor-receptor interactions of the opioid and anti-opioid systems are considered. These data can be useful for the design of new pharmaceuticals for pain relief. The generalization and study of these mechanisms are reflected in various approaches to treatment of pain syndromes and require analysis and further investigation.     

高效毛细管电泳法测定罂粟壳中生物碱的含量

采用高效毛细管电泳法测定罂粟壳中可待因、吗啡和罂粟碱的含量,结果表明可待因的加样回收率为９６．６１％,吗啡为９５．９０％,罂粟碱为９５．３７％。方法简便、准确、重现性好,可作为生物碱的质量控制方法。     

Paper spray mass spectrometry: A new drug checking tool for harm reduction in the opioid overdose crisis

Fentanyl and related psychoactive substances are at the forefront of the opioid overdose crisis, for which a complete solution is not immediately obvious. Drug testing for harm reduction may be an effective approach to both reduce overdoses and importantly, engage people who use drugs (PWUD) with the medical system. Paper spray mass spectrometry (PS‐MS) is an ambient ionization strategy that is uniquely suited to address this complicated analytical task. This perspectives article presents the merits of PS‐MS, with a focus upon the current state of its use as a candidate drug checking strategy for harm reduction. PS‐MS is inherently sensitive and selective, with detection limits in the picogram range. It requires small drug samples (~1 mg) for quantitative drug testing, critical to encourage pre‐consumption measurements by PWUD in the context of a harm reduction strategy. Calibrations obtained in surrogate drug matrices containing highly concentrated primary drugs demonstrate comparable sensitivities, a wide calibration range, and minimal matrix effects. PS‐MS can be interfaced with high‐resolution MS for non‐targeted analysis, allowing the identification of novel psychoactive substances as they appear in street drugs. Individual quantitative PS‐MS measurements for drug testing can be done in 1 minute or less, resulting in high sample throughput. Significant advancement in mass spectrometer miniaturization and mobilization has concomitant benefits for direct, on‐site drug checking, such as reduced cost, simplified maintenance and ease of use by less skilled operators. While PS‐MS technology continues to rapidly advance, it is our opinion that PS‐MS can be utilized as an effective tool for harm reduction in the opioid overdose crisis.     

Radiolabeling of codeine with 131I and its biodistribution in rats

Codeine which was extracted from dry capsules of the opium poppy (Papaver somniferum) was purified by HPLC (High Performance Liquid Chromatography) and characterized by NMR (Nuclear Magnetic Resonance) and IR (Infrared) spectroscopy techniques. The purified compound was labeled with ¹³¹I and biodistribution studies were performed in rats. Radioiodinated codeine distributed uniformly in the cerebellum, m.pons, striatum and hypothalamus while the other branch of brain and Stomach, urinary bladder, and small intestine uptakes were significantly higher than other tissues.     

Simultaneous quantification of nicotine,opioids, cocaine,and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry

A validated method for simultaneous LCMSMS quantification of nicotine, cocaine, 6-acetylmorphine (6AM), codeine, and metabolites in 100 mg fetal human brain was developed and validated. After homogenization and solid-phase extraction, analytes were resolved on a Hydro-RP analytical column with gradient elution. Empirically determined linearity was from 5–5,000 pg/mg for cocaine and benzoylecgonine (BE), 25–5,000 pg/mg for cotinine, ecgonine methyl ester (EME) and 6AM, 50-5000 pg/mg for trans-3-hydroxycotinine (OH-cotinine) and codeine, and 250–5,000 pg/mg for nicotine. Potential endogenous and exogenous interferences were resolved. Intra- and inter-assay analytical recoveries were ≥92%, intra- and inter-day and total assay imprecision were ≤14% RSD and extraction efficiencies were ≥67.2% with ≤83% matrix effect. Method applicability was demonstrated with a postmortem fetal brain containing 40 pg/mg cotinine, 65 pg/mg OH-cotinine, 13 pg/mg cocaine, 34 pg/mg EME, and 525 pg/mg BE. This validated method is useful for determination of nicotine, opioid, and cocaine biomarkers in brain.     

Mass spectrometric identification of peptide hormones in doping-control analysis

The identification power of mass spectrometry has enabled the determination of hundreds of prohibited drugs in doping-control analysis. A few years ago, its utility was extended to peptide hormones such as erythropoietins, synthetic insulins and corticotrophins detectable in blood or urine. New assays have been established to improve the fight against doping, employing highly selective and sensitive detection methods based on chromatographic and tandem mass spectrometric techniques. In particular, in light of recent scandals related to assumed peptide hormone misuse and attempts at the alteration of urine, sophisticated analytical tools are essential for obtaining unequivocal results in sports drug testing.     

Synthesis and Investigation of Mixed μ‐Opioid and δ‐Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain

Several studies have suggested functional association between μ‐opioid and δ‐opioid receptors and showed that μ‐activity could be modulated by δ‐ligands. The general conclusion is that agonists for the δ‐receptor can enhance the analgesic potency and efficacy of μ‐agonists. Our preliminary investigations demonstrate that new bivalent ligands constructed from the μ‐agonist fentanyl and the δ‐agonist enkephalin‐like peptides are promising entities for creation of new analgesics with reduced side effects for treatment of neuropathic pain. A new superposition of the mentioned pharmacophores led to novel μ‐bivalent/δ‐bivalent compounds that demonstrate both μ‐opioid and δ‐opioid receptor agonist activity and high efficacy in anti‐inflammatory and neuropathic pain models with the potential of reduced unwanted side effects.     

Eugenol: a natural compound with versatile pharmacological actions

Eugenol, the major constituent of clove oil, has been widely used for its anesthetic and analgesic action in dentistry. Eugenol exhibits pharmacological effects on almost all systems and our aim is to review the research work that has identified these pharmacological actions. Eugenol possesses significant antioxidant, anti-inflammatory and cardiovascular properties, in addition to analgesic and local anesthetic activity. The metabolism and pharmacokinetics of the compound in humans have been studied. Eugenol has also been used as a penetration enhancer. The compound is a very promising candidate for versatile applications, and the design of new drugs based on the pharmacological effects of eugenol could be beneficial.     

New enzyme sensors for morphine and codeine based on morphine dehydrogenase and laccase

Two new enzymatic methods have been developed to quantify morphine and codeine simultaneously in a flow injection system (FIA). The first enzyme sensor for morphine or codeine is based on immobilizing morphine dehydrogenase (MDH) and salicylate hydroxylase (SHL) on top of a Clark-type oxygen electrode. Morphine or codeine oxidation by MDH leads to a consumption of oxygen by SHL via the production of NADPH. This decreases the oxygen current of the Clark electrode. Concentrations of codeine and morphine are detected between 2 and 1000 μM and between 5 and 1000 μM, respectively. The second enzyme sensor for morphine is based on laccase (LACC) and PQQ-dependent glucose dehydrogenase (GDH) immobilized at a Clark oxygen electrode. Morphine is oxidized by laccase under consumption of oxygen and regenerated by glucose dehydrogenase. Since laccase cannot oxidize codeine, this sensor is selective for morphine. Morphine is detected between 32 nM and 100 μM. Both sensors can be operated simultaneously in one flow system (FIA) giving two signals without the requirement for a separation step. This rapid and technically simple method allows discrimination between morphine and codeine in less than 1 min after injection. The sampling rate for quantitative measurements is 20 h^–1. The method has been applied to the quantitative analysis of codeine or morphine in drugs. Received: 10 August 1998 / Revised: 29 January 1999 / Accepted: 5 February 1999